Purple Biotech Enters into Partnership with Mount Sinai for Research on CAPTN-3 Tri-Specific Antibody Platform
Tuesday, February 04, 2025
Purple Biotech has entered a research collaboration with the Icahn School of Medicine at Mount Sinai.
The partnership aims to investigate the immunoregulatory effects of the company’s CAPTN-3 multi-specific engagers on NK and T cells within the tumour microenvironment (TME). The goal is to enhance tumour-specific immune responses against various cancers.
The collaboration involves experts from the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute at Mount Sinai.
It is expected to provide deeper insights into the mechanisms of action of CAPTN-3, supporting its transition towards clinical trials. Multi-specific engagers have recently attracted increasing attention in oncology research, and this study will contribute to advancing CAPTN-3 development for future human trials.
Purple Biotech has entered a research collaboration with the Icahn School of Medicine at Mount Sinai.
The partnership aims to investigate the immunoregulatory effects of the company’s CAPTN-3 multi-specific engagers on NK and T cells within the tumour microenvironment (TME). The goal is to enhance tumour-specific immune responses against various cancers.
The collaboration involves experts from the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute at Mount Sinai.
It is expected to provide deeper insights into the mechanisms of action of CAPTN-3, supporting its transition towards clinical trials. Multi-specific engagers have recently attracted increasing attention in oncology research, and this study will contribute to advancing CAPTN-3 development for future human trials.
Source: globenewswire.com
